BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia

August 21, 2020 Auto Bot BioMarin, Children, FDA, NDA, Pharma, reports, Submission, Vosoritide 0

Shots:

  • BioMarin has submitted an NDA to the US FDA for vosoritide to treat children with achondroplasia
  • The company also reported that EMA has begun validation of MAA for the therapy on 13 Aug, 2020
  • Vosoritide is an investigational, once-daily injection analog of C-type Natriuretic Peptide (CNP) and is potentially the first treatment for achondroplasia in the US

Click here ­to­ read full press release/ article | Ref: Biomarin | Image: Fierce Biotech